Blood disorders
Lymphoma in Shanghai
上海 淋巴瘤
20 hospitals in Shanghai
Order: papers led on lymphoma, 2021–2025, then A–Z. Research activity, not a rating of care.
Only hospitals listed for lymphoma: those with enough papers or registered trials on it in the records this site uses. Other hospitals in Shanghai may also treat it. “Papers led” counts English-language PubMed papers whose first or last author lists the hospital first.
- 97 papers led
- 35 papers led
- 33 papers led
- 23 papers led
- 22 papers led
- 18 papers led
- 16 papers led
- 14 papers led
- 11 papers ledNo open trial led
- 11 papers led
- 10 papers ledNo open trial led
- 9 papers ledNo open trial led
- 7 papers ledNo open trial led
- 7 papers ledNo open trial led
- 6 papers ledNo open trial led
- 6 papers ledNo open trial led
- 5 papers ledNo open trial led
- 1 paper ledNo open trial led
- 0 papers ledNo open trial led
- 0 papers ledNo open trial led
Lymphoma in every city Shanghai on the disease page, with the national map
open trials on lymphoma with a hospital in Shanghai
Recruiting, not yet recruiting, or by invitation, as registered on ClinicalTrials.gov on 18 Nov 2026, with a listed hospital in Shanghai as lead sponsor or study site. 93 of them are led by a hospital in Shanghai. Check the registry for the current status. Whether someone can take part is decided by the study team.
Only trials registered on ClinicalTrials.gov are counted. Trials registered only in China’s own registry (ChiCTR) are not.
- RecruitingA Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
- Phase
- Phase 4
- Started
- 2026-03
- Posted
- Registry
- NCT07218341
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 12 listed hospitals as study sitesBeijing, Changsha, Guangzhou, Lanzhou, Nanchang, Shanghai, Tianjin, Urumqi, Xuzhou, Zhengzhou
- RecruitingGolidocitinib Versus Placebo as Maintenance Therapy for Peripheral T-Cell Lymphoma
- Phase
- Phase 3
- Started
- 2026-03
- Posted
- Registry
- NCT07300514
Age 18 years to Not stated (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- RecruitingT Cell Lymphoma -Stratified Therapy After Response to First-line Treatment-CR
- Phase
- Not given
- Started
- 2026-01
- Posted
- Registry
- NCT07353840
Age 18 years to 70 years (registered criteria)
Led by Shanghai General HospitalShanghai
- RecruitingPD-1 Antibody-based Therapy With Concurrent RT for Early-stage NKTCL
- Phase
- Phase 2
- Started
- 2026-03
- Posted
- Registry
- NCT07380984
Age 18 years to Not stated (registered criteria)
Led by Ruijin HospitalShanghai
- RecruitingUnrelated Cord Blood Transplantation for EBV-associated Lymphoproliferative Disorders
- Phase
- Phase 2
- Started
- 2026-01
- Posted
- Registry
- NCT07381738
Age 14 years to 80 years (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesShanghai
- RecruitingA Clinical Trial of Cidabenamine Plus Azacitidine to Prevent Post-Transplant Progression in High-Risk Peripheral T-Cell Lymphoma
- Phase
- Phase 2/Phase 3
- Started
- 2026-02
- Posted
- Registry
- NCT07389616
Age 18 years to 70 years (registered criteria)
Led by Shanghai General HospitalShanghai
- RecruitingA Phase III Study of HMPL-760 Plus R-GemOx VS Placebo Plus R-GemOx in Relapsed/Refractory DLBCL
- Phase
- Phase 3
- Started
- 2026-03
- Posted
- Registry
- NCT07409428
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 42 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Hangzhou, Harbin, Hefei, Jinan, Nanchang, Nanjing, Nanning, Qingdao, Quanzhou, Shanghai, Shenyang, Taiyuan, Tianjin, Wuhan, Xi'an, Xiamen, Xuzhou, Zhengzhou
- RecruitingGolidocitinib Versus Placebo as Maintenance Therapy in PTCL Patients With Response (CR/PR) After First-Line Chemotherapy
- Phase
- Phase 3
- Started
- 2026-02
- Posted
- Registry
- NCT07414758
Age 18 years to Not stated (registered criteria)
Led by Shanghai General HospitalShanghai
- RecruitingAssessing Treatment of T-Cell Lymphoma With GW5282 in Combination With Golidocitinib (BEI-DOU3)
- Phase
- Phase 1/Phase 2
- Started
- 2026-04
- Posted
- Registry
- NCT07496229
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 11 listed hospitals as study sitesChengdu, Chongqing, Fuzhou, Nanjing, Nanning, Shanghai, Taiyuan, Wenzhou, Wuhan, Zhengzhou
- RecruitingTislelizumab Plus Zeprumetostat for Relapsed or Refractory NK/T-Cell Lymphoma
- Phase
- Phase 1/Phase 2
- Started
- 2026-04
- Posted
- Registry
- NCT07502768
Age 18 years to Not stated (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- RecruitingChidamide Maintenance for MRD-Positive Double-Expressor DLBCL in First Complete Remission
- Phase
- Phase 2
- Started
- 2026-06
- Posted
- Registry
- NCT07507318
Age 18 years to 80 years (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- RecruitingThe Efficacy and Safety of Pola-ZR-Glo in Older Treatment-naive Patients With LBCL
- Phase
- Phase 2
- Started
- 2026-03
- Posted
- Registry
- NCT07514169
Age 70 years to Not stated (registered criteria)
Led by Ruijin HospitalShanghai
- RecruitingA Clinical Study of MK-1045 in People With Non-Hodgkin Lymphoma (MK-1045-008)
- Phase
- Phase 1/Phase 2
- Started
- 2026-05
- Posted
- Registry
- NCT07519772
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesBeijing, Fuzhou, Guangzhou, Shanghai, Zhengzhou
- RecruitingA Study of Rocbrutinib Combined With R-GemOx in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma
- Phase
- Phase 1
- Started
- 2026-06
- Posted
- Registry
- NCT07570017
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesGuangzhou, Shanghai
- RecruitingA Study of Automated Axicabtagene Ciloleucel for R/R Large B-cell Lymphoma.
- Phase
- Early phase 1
- Started
- 2026-06
- Posted
- Registry
- NCT07606937
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 4 listed hospitals as study sitesBeijing, Guangzhou, Shanghai, Tianjin
- RecruitingA Prospective Clinical Study on Reduced-intensity Radiotherapy for Stage I/II Low-risk Nasal-type NK/T-cell Lymphoma Achieving Complete Remission After Chemotherapy
- Phase
- Phase 2
- Started
- 2026-07
- Posted
- Registry
- NCT07628738
Age 18 years to 75 years (registered criteria)
Led by Ruijin HospitalShanghai
- RecruitingA Clinical Trial of MK-1045 and Rituximab in People With Follicular Lymphoma (MK-1045-007)
- Phase
- Phase 2/Phase 3
- Started
- 2026-06
- Posted
- Registry
- NCT07634471
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesBeijing, Shanghai
- RecruitingBRIDGE-NK: Immunotherapy Versus Chemotherapy Induction Followed by Autologous HSCT in Advanced NKTCL
- Phase
- Phase 3
- Started
- 2026-08
- Posted
- Registry
- NCT07678229
Age 18 years to 70 years (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- RecruitingClinical and Biological Cohort Study of EBV-Positive T/NK-Cell Lymphoproliferative Diseases
- Phase
- Not given
- Started
- 2026-08
- Posted
- Registry
- NCT07727083
Age 18 years to Not stated (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- RecruitingExploration of Circular RNA in B-cell Hematologic Malignancies
- Phase
- Phase 1
- Started
- 2026-05
- Posted
- Registry
- NCT07774572
Age 18 years to Not stated (registered criteria)
Led by Ruijin HospitalShanghai
- RecruitingA Phase I/II Trial of CT1190B in Patients With Relapsed/Refractory Large B-Cell Lymphoma
- Phase
- Phase 1/Phase 2
- Started
- 2026-09
- Posted
- Registry
- NCT07823829
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesShanghai, Wuhan
- RecruitingA Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
- Phase
- Phase 3
- Started
- 2025-01
- Posted
- Registry
- NCT06717347
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 20 listed hospitals as study sitesBeijing, Changchun, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Hefei, Jinan, Nanchang, Nanning, Nantong, Shanghai, Taiyuan, Tianjin, Wuhan, Xiamen
- RecruitingA Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)
- Phase
- Phase 3
- Started
- 2025-03
- Posted
- Registry
- NCT06742996
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 17 listed hospitals as study sitesBeijing, Chengdu, Chongqing, Guangzhou, Hangzhou, Harbin, Linyi, Nanchang, Nanjing, Qingdao, Shanghai, Shenyang, Wenzhou, Wuhan, Xuzhou, Zhengzhou
- RecruitingPOLA-R-CHP in the First-line Treatment of Transformed DLBCL
- Phase
- Phase 2
- Started
- 2025-02
- Posted
- Registry
- NCT06743945
Age 18 years to 80 years (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- RecruitingMZL-IPI Risk-adapted Targeted Therapy in Untreated MZL
- Phase
- Phase 2
- Started
- 2025-01
- Posted
- Registry
- NCT06793189
Age 18 years to Not stated (registered criteria)
Led by Ruijin Hospital; 2 listed hospitals as study sitesBeijing, Shanghai, Shenyang
- RecruitingEfficacy and Safety of Pola-RCHP-X vs Pola-RCHP in Untreated DLBCL
- Phase
- Phase 2
- Started
- 2025-04
- Posted
- Registry
- NCT06803693
Age 18 years to 75 years (registered criteria)
Led by Ruijin HospitalShanghai
- RecruitingClinical Trial of TQB2825 Injection Combined Immunochemotherapy in Subjects With Diffuse Large B Cell Lymphoma
- Phase
- Phase 1/Phase 2
- Started
- 2025-04
- Posted
- Registry
- NCT06829771
Age 18 years to 80 years (registered criteria)
Lead sponsor is not a listed hospital; 17 listed hospitals as study sitesBeijing, Bengbu, Changchun, Fuzhou, Guangzhou, Harbin, Lanzhou, Luzhou, Quanzhou, Shanghai, Taiyuan, Tianjin, Wuhan, Xi'an, Xuzhou, Yantai, Zhengzhou
- RecruitingNewly-diagnosed Pediatric T-cell ALL Protocol
- Phase
- Phase 2/Phase 3
- Started
- 2025-03
- Posted
- Registry
- NCT06855810
Age 1 month to 18 years (registered criteria)
Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMC; 13 listed hospitals as study sitesChangsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Hefei, Jinan, Qingdao, Shanghai, Tianjin, Wuhan
- RecruitingCD7 CAR T-Cell Therapy for r/r T-cell Lymphomas
- Phase
- Phase 1/Phase 2
- Started
- 2025-04
- Posted
- Registry
- NCT06925464
Age 14 years to 70 years (registered criteria)
Led by Beijing GoBroad Hospital; 1 listed hospital as study siteBeijing, Shanghai
- RecruitingA Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
- Phase
- Phase 3
- Started
- 2025-06
- Posted
- Registry
- NCT06943872
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 28 listed hospitals as study sitesBeijing, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hohhot, Jinan, Nanchang, Nanjing, Nanning, Qingdao, Shanghai, Shenyang, Shijiazhuang, Tianjin, Wuhan, Wuxi, Xiamen, Yangzhou
- RecruitingChimeric Antigen Receptor Natural Killer Cell Therapy for High-risk Lymphoma Patients With Primary Sjogren's Syndrome
- Phase
- Phase 1/Phase 2
- Started
- 2025-02
- Posted
- Registry
- NCT06967038
Age 18 years to 70 years (registered criteria)
Led by Tongji HospitalShanghai
- RecruitingA Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
- Phase
- Phase 3
- Started
- 2025-09
- Posted
- Registry
- NCT06973187
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 24 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Dalian, Fuzhou, Harbin, Lanzhou, Luzhou, Nanchang, Nanning, Nantong, Ningbo, Shanghai, Shenyang, Shijiazhuang, Suzhou, Taiyuan, Wenzhou, Wuhan, Xi'an, Xining, Xuzhou, Zhengzhou
- RecruitingEfficacy and Safety Evaluation of U01(ssCART-19) in B-Cell Lymphoma
- Phase
- Phase 1/Phase 2
- Started
- 2025-04
- Posted
- Registry
- NCT06987916
Age 2 years to 75 years (registered criteria)
Led by Tongji HospitalShanghai
- RecruitingEvaluation of the Efficacy and Safety of Polatuzumab Vedotin Combined With Rituximab, Gemcitabine, and Oxaliplatin (Pola-R-GemOx) as Salvage Therapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Patients Ineligible for Autologous Transplantation
- Phase
- Phase 2
- Started
- 2025-05
- Posted
- Registry
- NCT07001540
Age 18 years to Not stated (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- RecruitingRGL-305+ Lymphoma + Exploratory Clinical Study
- Phase
- N/A
- Started
- 2025-04
- Posted
- Registry
- NCT07006012
Age 18 years to 75 years (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- RecruitingGlofitamab, Polatuzumab Vedotin and Zanubrutinib in First-line Elderly DLBCL
- Phase
- Phase 2
- Started
- 2025-06
- Posted
- Registry
- NCT07012980
Age 70 years to Not stated (registered criteria)
Led by Zhongshan Hospital, Fudan UniversityShanghai
- RecruitingCD5 CAR T-Cell Therapy for r/r T-cell Lymphomas
- Phase
- Phase 1/Phase 2
- Started
- 2025-06
- Posted
- Registry
- NCT07022964
Age 14 years to 70 years (registered criteria)
Led by Beijing GoBroad Hospital; 1 listed hospital as study siteBeijing, Shanghai
- RecruitingA Clinical Study Exploring CT1190B in the Treatment of Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma ( CT1190B-CG11001 )
- Phase
- Phase 1
- Started
- 2025-07
- Posted
- Registry
- NCT07053670
Age 18 years to 75 years (registered criteria)
Led by Tongji Hospital; 1 listed hospital as study siteShanghai, Wuhan
- RecruitingStudy on Predicting Response to Standard First-Line Treatment in Diffuse Large B-Cell Lymphoma (DLBCL) Patients Using ctDNA Combined With PET
- Phase
- Not given
- Started
- 2025-05
- Posted
- Registry
- NCT07070648
Age 18 years to Not stated (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- RecruitingA Study of mRNA Encoding CD19/CD3 T Cell Engager (ABO2203) in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (B-NHL)
- Phase
- Phase 1
- Started
- 2025-05
- Posted
- Registry
- NCT07072169
Age 18 years to 75 years (registered criteria)
Led by Ruijin HospitalShanghai
- RecruitingThe Safety, Tolerability, and Efficacy of IBR900 Cell Injection in Relapsed/Refractory B-cell Non Hodgkin Lymphoma
- Phase
- Phase 1
- Started
- 2025-07
- Posted
- Registry
- NCT07073833
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesHangzhou, Shanghai
- RecruitingA Study to Evaluate the Efficacy and Safety of ICP-248 in Subjects With Relapsed or Refractory Mantle Cell Lymphoma (APEX-06)
- Phase
- Phase 2
- Started
- 2025-08
- Posted
- Registry
- NCT07082686
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 27 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Hefei, Jinan, Nanchang, Nanjing, Nanning, Qingdao, Shanghai, Tianjin, Urumqi, Wuhan, Xi'an, Zhengzhou
- RecruitingClinical Study of U01(ssCART-19) in Patients With B-Cell Lymphoma
- Phase
- Phase 1
- Started
- 2025-01
- Posted
- Registry
- NCT07093073
Age 2 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- RecruitingSafety and Efficacy of Anti-EBV Autologous TCR-T Cell Injection in Relapsed/Refractory EBV-Positive Lymphoma
- Phase
- Early phase 1
- Started
- 2025-09
- Posted
- Registry
- NCT07162012
Age 18 years to 70 years (registered criteria)
Led by Shanghai General HospitalShanghai
- RecruitingChemotherapy With Rituximab for Aggressive B-NHL in Children and Adolescents
- Phase
- Phase 2/Phase 3
- Started
- 2025-07
- Posted
- Registry
- NCT07168980
Age Not stated to 18 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- RecruitingOrelabrutinib Combined With Teniposide, Rituximab and Methotrexate for Newly Diagnosed PCNSL
- Phase
- Phase 2/Phase 3
- Started
- 2025-10
- Posted
- Registry
- NCT07185373
Age 18 years to 75 years (registered criteria)
Led by Huashan Hospital; 11 listed hospitals as study sitesBeijing, Fuzhou, Guangzhou, Jinan, Nanchang, Shanghai, Xi'an, Zhengzhou
- RecruitingPA3-17 Injection in Adult Patients With CD7-positive Relapsed/Refractory T-lymphoblastic Leukemia/Lymphoma
- Phase
- Phase 2
- Started
- 2025-09
- Posted
- Registry
- NCT07188610
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 15 listed hospitals as study sitesBeijing, Chengdu, Guangzhou, Hangzhou, Hefei, Nanjing, Shanghai, Suzhou, Tianjin, Wuhan, Xuzhou, Zhengzhou
- RecruitingA Study of Rocbrutinib in Participants With Relapse or Refractory Non-GCB Diffuse Large B-Cell Lymphoma
- Phase
- Phase 2
- Started
- 2025-11
- Posted
- Registry
- NCT07189065
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 38 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Dalian, Fuzhou, Guangzhou, Hangzhou, Hefei, Linyi, Luoyang, Nanchang, Nanjing, Nanning, Shanghai, Shenyang, Shijiazhuang, Suzhou, Taiyuan, Tianjin, Wuhan, Xiamen, Xuzhou, Zhengzhou
- RecruitingA Clinical Study on the Efficacy and Safety of Methotrexate (MTX) or Thiotepa (for MTX Intolerance) or Temozolomide (TMZ) Combined With Orelabrutinib and Selinexor in Relapsed/Refractory Primary or Secondary Central Nervous System Lymphoma(SELINA)
- Phase
- N/A
- Started
- 2025-09
- Posted
- Registry
- NCT07191431
Age 14 years to 80 years (registered criteria)
Led by Ruijin HospitalShanghai
- RecruitingOrelabrutinib and Rituximab With Optional Autologous Hematopoietic Stem Cell Transplantation in MCL Treatment
- Phase
- Phase 2
- Started
- 2025-07
- Posted
- Registry
- NCT07199296
Age 14 years to Not stated (registered criteria)
Led by Ruijin HospitalShanghai
- RecruitingAn Observational Study of Glofitamab in Chinese Adult Participants With 2L Diffuse Large B-Cell Lymphoma
- Phase
- Not given
- Started
- 2025-09
- Posted
- Registry
- NCT07200375
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 18 listed hospitals as study sitesBeijing, Changchun, Chengdu, Guangzhou, Harbin, Jinan, Nanchang, Ningbo, Shanghai, Tianjin, Wenzhou, Wuhan, Xi'an, Yantai, Zhengzhou
- RecruitingUniversal CAR-T Cell Therapy for NHL
- Phase
- N/A
- Started
- 2025-03
- Posted
- Registry
- NCT07248163
Age 18 years to Not stated (registered criteria)
Led by Tongji HospitalShanghai
- RecruitingAllo-HSCT Vs. Auto-HSCT for PTCL Patients With PR After First-line Systemic Therapy : A Prospective, Multicenter, Cohort Study-(T-START-PR)
- Phase
- Not given
- Started
- 2025-12
- Posted
- Registry
- NCT07253129
Age 18 years to 70 years (registered criteria)
Led by Shanghai General HospitalShanghai
- RecruitingReal-world Outcomes of Peripheral T-cell Lymphoma: A Multicenter Retrospective and Prospective Cohort Study
- Phase
- Not given
- Started
- 2025-11
- Posted
- Registry
- NCT07270861
Age 18 years to Not stated (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- RecruitingOrelabrutinib Plus Lisaftoclax and Rituximab in Untreated Mantle Cell Lymphoma With High-Risk Disease
- Phase
- Phase 2
- Started
- 2025-09
- Posted
- Registry
- NCT07272499
Age 14 years to Not stated (registered criteria)
Led by Ruijin HospitalShanghai
- RecruitingT Cell Lymphoma -Stratified Therapy After Response to First-line Treatment-NR
- Phase
- Not given
- Started
- 2025-10
- Posted
- Registry
- NCT07470996
Age 18 years to 70 years (registered criteria)
Led by Shanghai General HospitalShanghai
- RecruitingEfficacy and Safety of Chidamide Combined With PD-1 Inhibitor as Maintenance Therapy Following CAR-T Cell Treatment With TP53-Mutated Large B-Cell Lymphoma (LBCL)
- Phase
- Phase 4
- Started
- 2025-10
- Posted
- Registry
- NCT07934537
Age 18 years to 70 years (registered criteria)
Led by Tongji HospitalShanghai
- RecruitingA Study of GLB-002 in Patients With Relapsed or Refractory Non-Hodgkin Lymphomas
- Phase
- Phase 1
- Started
- 2024-01
- Posted
- Registry
- NCT06219356
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 12 listed hospitals as study sitesBeijing, Changsha, Guangzhou, Hangzhou, Nanchang, Shanghai, Shenyang, Taiyuan, Wuhan, Xiamen, Zhengzhou
- RecruitingOrelabrutinib in the Treatment of HP-positive Gastric MALT Lymphoma
- Phase
- Phase 2
- Started
- 2024-03
- Posted
- Registry
- NCT06228963
Age 18 years to Not stated (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- RecruitingScreening Study of Combined Sequential Chemotherapy and Radiation Therapy for Early-stage NK/T-cell Lymphoma
- Phase
- Phase 2
- Started
- 2024-03
- Posted
- Registry
- NCT06314334
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 4 listed hospitals as study sitesHangzhou, Shanghai
- RecruitingA Multicenter, Prospective, Phase II Study of Zanubrutinib for Maintenance in Patients With Mantle Cell Lymphoma
- Phase
- Phase 2
- Started
- 2024-05
- Posted
- Registry
- NCT06341556
Age 18 years to Not stated (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- RecruitingA Global Phase 3 Study of Orelabrutinib+BR Vs.BR in Pts with TN MCL
- Phase
- Phase 3
- Started
- 2024-05
- Posted
- Registry
- NCT06363994
Age 60 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 31 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Changzhou, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Hefei, Jinan, Luoyang, Nanchang, Nanjing, Ningbo, Shanghai, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Urumqi, Wuhan, Xi'an, Zhengzhou
- RecruitingCAR-T Following ASCT for Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (R/R B-NHL) With High-Risk Prognostic Factors
- Phase
- Phase 2
- Started
- 2024-04
- Posted
- Registry
- NCT06365671
Age 18 years to Not stated (registered criteria)
Led by Ruijin HospitalShanghai
- RecruitingICP-248 in Combination With Orelabrutinib in Treatment-naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (APEX-03)
- Phase
- Phase 2/Phase 3
- Started
- 2024-05
- Posted
- Registry
- NCT06378138
Age 18 years to 80 years (registered criteria)
Lead sponsor is not a listed hospital; 43 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Dalian, Fuzhou, Guangzhou, Hangzhou, Hefei, Huai'an, Jinan, Lanzhou, Luoyang, Nanchang, Nanjing, Nanning, Shanghai, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Urumqi, Wuhan, Xi'an, Xiamen, Yichang, Zhengzhou, Zunyi
- RecruitingStudy Evaluating ISM8207 in Participants With Advanced Solid Tumors and Relapsed/Refractory B-Cell Lymphoma
- Phase
- Phase 1
- Started
- 2024-04
- Posted
- Registry
- NCT06445517
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 4 listed hospitals as study sitesBeijing, Nanchang, Shanghai, Tianjin
- RecruitingCD19/CD22 CAR-T Cells in Adults With R/R ALL or NHL
- Phase
- Phase 1
- Started
- 2024-05
- Posted
- Registry
- NCT06445803
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesNanchang, Shanghai
- RecruitingA Cohort Study in Newly Diagnosed MZL
- Phase
- Not given
- Started
- 2024-05
- Posted
- Registry
- NCT06449885
Age 18 years to Not stated (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- RecruitingStudy of AXT-1003 in Subjects With Advanced Malignant Tumors.
- Phase
- Phase 1
- Started
- 2024-09
- Posted
- Registry
- NCT06484985
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 4 listed hospitals as study sitesBeijing, Fuzhou, Guangzhou, Shanghai
- RecruitingA Study of LCAR-HL30 in Subjects With Relapsed/Refractory Hodgkin's Lymphoma and Anaplastic Large Cell Lymphoma
- Phase
- Phase 1
- Started
- 2024-07
- Posted
- Registry
- NCT06494371
Age 18 years to 75 years (registered criteria)
Led by Ruijin HospitalShanghai
- RecruitingBendamustine and Rituximab With or Without Orelabrutinib in MCL Treatment
- Phase
- Phase 3
- Started
- 2024-07
- Posted
- Registry
- NCT06496308
Age 18 years to 80 years (registered criteria)
Led by Ruijin HospitalShanghai
- RecruitingAn Open-label, Single-arm Study of JWCAR201 in the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma
- Phase
- Phase 1
- Started
- 2024-07
- Posted
- Registry
- NCT06517004
Age 18 years to Not stated (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- RecruitingSelinexor in Combination With R-CHOP as the First-line Therapy for TP53-mutated DLBCL Patients (Smart Trial)
- Phase
- Phase 2
- Started
- 2024-08
- Posted
- Registry
- NCT06517511
Age 18 years to 80 years (registered criteria)
Led by Sun Yat-sen University Cancer Center; 1 listed hospital as study siteGuangzhou, Shanghai
- RecruitingExploratory Clinical Study of SHR-0302 and SHR-2554 in Patients With Relapsed/Refractory Peripheral T Cell Lymphoma
- Phase
- Phase 2
- Started
- 2024-08
- Posted
- Registry
- NCT06519526
Age 18 years to 70 years (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- RecruitingEvaluate the Safety and Efficacy of Tafasitamab and Lenalidomide in Combination With Gemcitabine and Oxaliplatin Versus Rituximab in Combination With Gemcitabine and Oxaliplatin in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
- Phase
- Phase 3
- Started
- 2024-05
- Posted
- Registry
- NCT06521255
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 19 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Jinan, Nanchang, Shanghai, Suzhou, Tianjin, Urumqi, Wenzhou, Wuhan, Zhengzhou
- RecruitingThe Efficacy and Safety of Pola-ZR2 Versus ZR2 in the Treatment of Old Patients With de Novo Diffuse Large B-cell Lymphoma
- Phase
- Phase 3
- Started
- 2024-07
- Posted
- Registry
- NCT06522555
Age 70 years to Not stated (registered criteria)
Led by Ruijin HospitalShanghai
- RecruitingRegistry Study of Chinese Patients with Marginal Zone Lymphoma (MOTIVE)
- Phase
- Not given
- Started
- 2024-08
- Posted
- Registry
- NCT06534463
Age 14 years to Not stated (registered criteria)
Led by Ruijin HospitalShanghai
- RecruitingCellular Immunotherapy for Relapsed or Refractory Lymphoma Data Collection
- Phase
- Not given
- Started
- 2024-05
- Posted
- Registry
- NCT06541327
Age 18 years to Not stated (registered criteria)
Led by Ruijin HospitalShanghai
- RecruitingBrentuximab Vedotin for Newly Diagnosed cHL in Chinese CAYA Based on PET/CT Assessment
- Phase
- Phase 2/Phase 3
- Started
- 2024-09
- Posted
- Registry
- NCT06563245
Age 2 years to 35 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- RecruitingA Clinical Study to Evaluate the Efficacy and Safety of TQB3702 Tablets Combined With Immunochemotherapy for the Treatment of B-cell Lymphoma
- Phase
- Phase 2
- Started
- 2024-11
- Posted
- Registry
- NCT06566586
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 16 listed hospitals as study sitesChangsha, Guangzhou, Harbin, Hohhot, Lanzhou, Luzhou, Nanchang, Nanning, Shanghai, Taiyuan, Tianjin, Urumqi, Wuhan, Xi'an, Zhengzhou
- RecruitingBCL-2 Inhibitors Combined with the HyperCVAD Regimen for Newly Diagnosed T-lymphoblastic Leukemia/lymphoma.
- Phase
- Phase 2
- Started
- 2024-08
- Posted
- Registry
- NCT06598722
Age 18 years to 60 years (registered criteria)
Led by Shanghai General HospitalShanghai
- RecruitingDemethylating Agents Combined With Venetoclax for High-risk T-cell Lymphoblastic Lymphoma/Leukemia Post-Transplant Relapse Prevention
- Phase
- Phase 2
- Started
- 2024-10
- Posted
- Registry
- NCT06686108
Age 14 years to 55 years (registered criteria)
Led by Shanghai General HospitalShanghai
- RecruitingA Clinical Study Exploring CT1190B in the Treatment of Patients with Relapsed/refractory B-cell Non-Hodgkin Lymphoma
- Phase
- Phase 1
- Started
- 2024-12
- Posted
- Registry
- NCT06734871
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- RecruitingPET Imaging Targeting Granzyme B Predicts Immunotherapy Efficacy in Diffuse Large B-cell Lymphoma
- Phase
- Not given
- Started
- 2024-07
- Posted
- Registry
- NCT06755775
Age 18 years to Not stated (registered criteria)
Led by Ruijin HospitalShanghai
- RecruitingCD70-targeted immunoPET Imaging of Malignant Cancers
- Phase
- Phase 2
- Started
- 2024-12
- Posted
- Registry
- NCT06852638
Age 18 years to 80 years (registered criteria)
Led by Renji HospitalShanghai
- RecruitingA Phase 3 Multinational Study of Golidocitinib Versus Investigator's Choice in r/r PTCL (JACKPOT19)
- Phase
- Phase 3
- Started
- 2024-05
- Posted
- Registry
- NCT07234162
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 35 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Lanzhou, Linyi, Nanjing, Nanning, Shanghai, Shenyang, Taiyuan, Tianjin, Wenzhou, Wuhan, Xi'an, Xiamen, Zhengzhou
- RecruitingPredictive Factors for the Efficacy of CD19 CAR-T Therapy in Relapsed/Refractory Large B-Cell Lymphoma: A Clinical Study
- Phase
- Not given
- Started
- 2024-02
- Posted
- Registry
- NCT07236203
Age 18 years to Not stated (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- RecruitingGenotype-guided Treatment in Newly Diagnosed PTCL
- Phase
- Phase 1/Phase 2
- Started
- 2023-02
- Posted
- Registry
- NCT05675813
Age 18 years to 75 years (registered criteria)
Led by Ruijin HospitalShanghai
- RecruitingCapizzi Escalating Methotrexate Versus High Dose Methotrexate in Children With Newly Diagnosed T-cell Lymphoblastic Lymphoma (T-LBL)
- Phase
- Phase 3
- Started
- 2023-02
- Posted
- Registry
- NCT05681260
Age 12 months to 18 years (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesChengdu, Shanghai
- RecruitingSelinexor in Combination With MTX+Ritu to Treat R/R CNSL
- Phase
- Phase 1/Phase 2
- Started
- 2023-08
- Posted
- Registry
- NCT05698147
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 5 listed hospitals as study sitesBeijing, Fuzhou, Hefei, Shanghai, Zhengzhou
- RecruitingClinical Study of U16 in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
- Phase
- Phase 1/Phase 2
- Started
- 2023-03
- Posted
- Registry
- NCT05768529
Age 18 years to 70 years (registered criteria)
Lead sponsor is not a listed hospital; 3 listed hospitals as study sitesChangsha, Shanghai, Suzhou
- RecruitingA Study of C-CAR039 (Prizloncabtagene Autoleucel) in Patients With Relapsed/Refractory Large B-Cell Lymphoma
- Phase
- Phase 1/Phase 2
- Started
- 2023-02
- Posted
- Registry
- NCT05800977
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 14 listed hospitals as study sitesBeijing, Chongqing, Guangzhou, Hangzhou, Nanchang, Nanjing, Shanghai, Tianjin, Zhengzhou
- RecruitingSecondary Infusion of Relma-cel Injection for Relapsed or Refractory B-cell Lymphoma
- Phase
- Phase 4
- Started
- 2023-05
- Posted
- Registry
- NCT05806580
Age 18 years to Not stated (registered criteria)
Led by Ruijin HospitalShanghai
- RecruitingStudy of Cord Blood-derived CAR NK Cells Targeting CD19/CD70 in Refractory/Relapsed B-cell Non-Hodgkin Lymphoma
- Phase
- Phase 1/Phase 2
- Started
- 2023-01
- Posted
- Registry
- NCT05842707
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- RecruitingA Real-world Study of Obinutuzumab-based Therapy for Previously Untreated FL
- Phase
- Not given
- Started
- 2023-06
- Posted
- Registry
- NCT05899621
Age 18 years to Not stated (registered criteria)
Led by Ruijin HospitalShanghai
- RecruitingReal-World Study of DLBCL With Different Genetic Subtypes
- Phase
- Not given
- Started
- 2023-10
- Posted
- Registry
- NCT06026488
Age 18 years to Not stated (registered criteria)
Led by Ruijin HospitalShanghai
- RecruitingPET and EBV DNA-directed Therapy for Localized Nasal Extranodal NK/T Cell Lymphoma
- Phase
- N/A
- Started
- 2023-12
- Posted
- Registry
- NCT06069830
Age 18 years to Not stated (registered criteria)
Led by Ruijin HospitalShanghai
- RecruitingEfficacy and Safety of Orelabrutinib Combined With Rituximab Versus Lenalidomide Combined With Rituximab in Patients With Relapsed/Refractory Marginal Zone Lymphoma
- Phase
- Phase 3
- Started
- 2023-12
- Posted
- Registry
- NCT06082102
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 18 listed hospitals as study sitesBeijing, Bengbu, Changsha, Chengdu, Dalian, Guangzhou, Hangzhou, Nanchang, Qingdao, Shanghai, Shenyang, Wuhan, Xi'an, Yantai, Zhengzhou
- RecruitingA Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma
- Phase
- Phase 3
- Started
- 2023-10
- Posted
- Registry
- NCT06084936
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 12 listed hospitals as study sitesBeijing, Changchun, Chengdu, Chongqing, Fuzhou, Guangzhou, Nanning, Shanghai, Shenyang, Wenzhou, Zhengzhou
- RecruitingA Study of the Zanubrutinib Given in Combination With Bendamustine and Rituximab in (Elderly or TP53 Alterations or Chemotherapy Intolerance) Patients With Newly Diagnosed Mantle Cell Lymphoma
- Phase
- Phase 2
- Started
- 2023-11
- Posted
- Registry
- NCT06136351
Age 18 years to Not stated (registered criteria)
Led by Ruijin HospitalShanghai
- RecruitingCD7 CAR-T in Adults With Relapsed or Refractory T-LBL/ALL Clinical Study
- Phase
- Phase 1
- Started
- 2023-08
- Posted
- Registry
- NCT06136364
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- RecruitingThe Pathogenesis and Prognostic Factors of Lymphoma
- Phase
- Not given
- Started
- 2023-06
- Posted
- Registry
- NCT06203652
Age not stated (registered criteria)
Led by Zhongshan Hospital, Fudan UniversityShanghai
- RecruitingThe Treatment of Ocular Adnexal Extranodal Marginal Zone B-cell Lymphoma by Orelabrutinib and Radiotherapy
- Phase
- Phase 2
- Started
- 2023-11
- Posted
- Registry
- NCT06503276
Age 18 years to 75 years (registered criteria)
Led by Shanghai Ninth People's HospitalShanghai
- RecruitingRelma-cel Followed by Tislelizumab for the Treatment of Relapsed/Refractory CNS Large B-Cell Lymphoma
- Phase
- Phase 2
- Started
- 2023-11
- Posted
- Registry
- NCT06876688
Age 18 years to Not stated (registered criteria)
Led by Ruijin Hospital; 5 listed hospitals as study sitesBeijing, Guangzhou, Shanghai, Wuhan, Zhengzhou
- RecruitingCell Free DNA in Mature B-cell Lymphoma
- Phase
- Not given
- Started
- 2022-09
- Posted
- Registry
- NCT04088422
Age 18 years to Not stated (registered criteria)
Led by Ruijin HospitalShanghai
- RecruitingA Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)
- Phase
- Phase 2/Phase 3
- Started
- 2022-01
- Posted
- Registry
- NCT05139017
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 15 listed hospitals as study sitesBeijing, Changchun, Chengdu, Chongqing, Guangzhou, Hangzhou, Luoyang, Nanchang, Shanghai, Wuhan, Zhengzhou
- RecruitingA Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
- Phase
- Phase 3
- Started
- 2022-07
- Posted
- Registry
- NCT05254743
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 15 listed hospitals as study sitesChangsha, Guangzhou, Haikou, Hangzhou, Hefei, Nanchang, Nanning, Shanghai, Tianjin, Urumqi, Wuhan
- RecruitingTreatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader
- Phase
- Phase 1/Phase 2
- Started
- 2022-05
- Posted
- Registry
- NCT05294731
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 21 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Hefei, Jinan, Nanchang, Nanjing, Qingdao, Shanghai, Suzhou, Taiyuan, Wenzhou, Wuhan, Zhengzhou
- RecruitingEfficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)
- Phase
- Phase 2
- Started
- 2021-04
- Posted
- Registry
- NCT04728893
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 17 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Guangzhou, Hangzhou, Hefei, Nanchang, Nanjing, Nanning, Shanghai, Tianjin, Wuhan, Xuzhou, Zhengzhou
- RecruitingA Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
- Phase
- Phase 1/Phase 2
- Started
- 2021-09
- Posted
- Registry
- NCT05006716
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 7 listed hospitals as study sitesBeijing, Guangzhou, Shanghai, Tianjin, Wenzhou, Yichang, Zhengzhou
- RecruitingThe Safety and Effectiveness of 4R-CHOP+4R vs 6R-CHOP+2R in Newly Diagnosed Patients With DLBCL in Low Risk
- Phase
- Phase 3
- Started
- 2021-09
- Posted
- Registry
- NCT05018520
Age 14 years to 75 years (registered criteria)
Led by Ruijin HospitalShanghai
- RecruitingA Study to Evaluate MK-1045 (CN201) in Participants With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (MK-1045-001/CN201-101)
- Phase
- Phase 1
- Started
- 2021-03
- Posted
- Registry
- NCT06189391
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 15 listed hospitals as study sitesBeijing, Changchun, Chengdu, Guangzhou, Jinan, Nanchang, Shanghai, Shijiazhuang, Tianjin, Xiamen, Zhengzhou
- RecruitingA Study of JMT601 in Participants With Relapsed or Refractory CD20-positive B-cell Non-Hodgkin Lymphoma
- Phase
- Phase 1
- Started
- 2021-10
- Posted
- Registry
- NCT06725524
Age 18 years to 70 years (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- RecruitingStudy to Evaluate Efficacy and Safety of Oral Abexinostat in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)
- Phase
- Phase 2
- Started
- 2020-01
- Posted
- Registry
- NCT03936153
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 15 listed hospitals as study sitesBeijing, Chengdu, Fuzhou, Hangzhou, Lanzhou, Linyi, Shanghai, Shijiazhuang, Wuhan, Xuzhou, Zhengzhou
- RecruitingEvaluate the Safety and Clinical Activity of HH2853
- Phase
- Phase 1/Phase 2
- Started
- 2020-09
- Posted
- Registry
- NCT04390737
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 15 listed hospitals as study sitesBeijing, Changsha, Chengdu, Guangzhou, Hangzhou, Hefei, Nanjing, Nanning, Shanghai, Shenyang, Taiyuan, Tianjin, Wuhan, Zhengzhou
- RecruitingStudy of APG2575 Single Agent and Combination Therapy in Patients With Relapsed/Refractory CLL/SLL
- Phase
- Phase 1/Phase 2
- Started
- 2020-08
- Posted
- Registry
- NCT04494503
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 17 listed hospitals as study sitesBeijing, Changchun, Changsha, Chongqing, Guangzhou, Guiyang, Hangzhou, Nanchang, Nanjing, Nanning, Shanghai, Shijiazhuang, Suzhou, Tianjin, Wuhan
- RecruitingPhase II Clinical Trial of CNCT19 Cell Injection in the Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma
- Phase
- Phase 2
- Started
- 2020-10
- Posted
- Registry
- NCT04586478
Age 18 years to 75 years (registered criteria)
Lead sponsor is not a listed hospital; 16 listed hospitals as study sitesBeijing, Chengdu, Chongqing, Guangzhou, Hangzhou, Jinan, Shanghai, Tianjin, Wuhan, Zhengzhou
- RecruitingPhase Ib Clinical Study of Keynatinib
- Phase
- Phase 1
- Started
- 2020-09
- Posted
- Registry
- NCT04807881
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 4 listed hospitals as study sitesBeijing, Chengdu, Shanghai
- RecruitingOptimization of 18F-FDG PET/CT Response Assessment and Prognostic Evaluation Strategies for High-Metabolism Lymphoma
- Phase
- Not given
- Started
- 2013-06
- Posted
- Registry
- NCT06795113
Age 18 years to 100 years (registered criteria)
Led by Ruijin HospitalShanghai
- Not yet recruitingA Clinical Trial of B019 Injection in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma.
- Phase
- Phase 1
- Started
- 2026-08
- Posted
- Registry
- NCT06970496
Age 18 years to 70 years (registered criteria)
Lead sponsor is not a listed hospital; 7 listed hospitals as study sitesGuangzhou, Nanchang, Shanghai, Wenzhou, Xi'an
- Not yet recruitingClinical Study of XP-006 mRNA Vaccine for R/R B-NHL
- Phase
- Phase 1
- Started
- 2026-01
- Posted
- Registry
- NCT07334574
Age 18 years to Not stated (registered criteria)
Led by Ruijin HospitalShanghai
- Not yet recruitingZillion: Zanubrutinib Combined With Chemotherapy for Newly Diagnosed CNS Lymphoma
- Phase
- Phase 2
- Started
- 2026-01
- Posted
- Registry
- NCT07405255
Age 18 years to 80 years (registered criteria)
Led by Ruijin HospitalShanghai
- Not yet recruitingA Study Comparing C Pola R-CHP+X With CR-CHOP in the Treatment of Previously Untreated DEL Under the Guidance of Genotyping
- Phase
- Phase 3
- Started
- 2026-03
- Posted
- Registry
- NCT07511114
Age 18 years to 75 years (registered criteria)
Led by Ruijin HospitalShanghai
- Not yet recruitingAclarubicin Plus Cyclophosphamide, Vincristine, and Prednisone (CAOP) in Patients With Previously Treated Cutaneous T-cell Lymphoma
- Phase
- Phase 1/Phase 2
- Started
- 2026-03
- Posted
- Registry
- NCT07535710
Age 60 years to Not stated (registered criteria)
Led by Ruijin HospitalShanghai
- Not yet recruitingAclarubicin Plus Cyclophosphamide, Vincristine, and Prednisone (CAOP) in Patients With Previously Untreated Peripheral T-Cell Lymphoma
- Phase
- Phase 2
- Started
- 2026-03
- Posted
- Registry
- NCT07535762
Age 65 years to Not stated (registered criteria)
Led by Ruijin HospitalShanghai
- Not yet recruitingThe Efficacy and Safety of Sonrotoclax, Zanubrutinib Combined With Obinutuzumab in MCL
- Phase
- Phase 1
- Started
- 2026-04
- Posted
- Registry
- NCT07548255
Age 18 years to Not stated (registered criteria)
Led by Ruijin HospitalShanghai
- Not yet recruitingA Phase Ⅰ Study of CS08399 in Participants With MTAP-deleted Solid Tumors and Lymphoma
- Phase
- Phase 1
- Started
- 2026-06
- Posted
- Registry
- NCT07583771
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 1 listed hospital as study siteShanghai
- Not yet recruitingAI-Driven Treatment Strategy vs Pola-R-CHP in Untreated LBCL
- Phase
- Phase 2
- Started
- 2026-05
- Posted
- Registry
- NCT07594899
Age 18 years to 75 years (registered criteria)
Led by Ruijin HospitalShanghai
- Not yet recruitingLME-Guided Precision Combination Therapy in B-cell Lymphoma Patients After CD19 CAR-T Failure
- Phase
- Phase 2
- Started
- 2026-05
- Posted
- Registry
- NCT07602322
Age 18 years to Not stated (registered criteria)
Led by Ruijin HospitalShanghai
- Not yet recruitingRimegepant Plus Glofitamab and CD19 CAR-T Therapy in R/R LBCL
- Phase
- Phase 2
- Started
- 2026-05
- Posted
- Registry
- NCT07613788
Age 18 years to Not stated (registered criteria)
Led by Ruijin HospitalShanghai
- Not yet recruitingPola-R-CHP Plus Sonrotoclax in Untreated BCL2-High/Double-Hit LBCL
- Phase
- Phase 1/Phase 2
- Started
- 2026-06
- Posted
- Registry
- NCT07638787
Age 18 years to 75 years (registered criteria)
Led by Ruijin HospitalShanghai
- Not yet recruitingA Prospective Study of Response-adapted Low-dose Radiotherapy Combined With Orelabrutinib for Localized Mucosa-associated Lymphoid Tissue Extranodal Marginal Zone Lymphoma
- Phase
- Phase 2
- Started
- 2026-08
- Posted
- Registry
- NCT07705308
Age 18 years to Not stated (registered criteria)
Led by Ruijin Hospital; 2 listed hospitals as study sitesShanghai
- Not yet recruitingNew Genotype-guided Treatment in Newly Diagnosed PTCL
- Phase
- Phase 1/Phase 2
- Started
- 2026-07
- Posted
- Registry
- NCT07706959
Age 18 years to 75 years (registered criteria)
Led by Ruijin HospitalShanghai
- Not yet recruitingBirelentinib Plus R-CHOP in Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma (TAI-SHAN19)
- Phase
- Phase 2/Phase 3
- Started
- 2026-09
- Posted
- Registry
- NCT07712588
Age 18 years to 70 years (registered criteria)
Lead sponsor is not a listed hospital; 4 listed hospitals as study sitesChangsha, Chongqing, Harbin, Shanghai
- Not yet recruitingAI-Driven Treatment Strategy vs ZR2 in Older Treatment-naive Patients With LBCL
- Phase
- Phase 2
- Started
- 2026-06
- Posted
- Registry
- NCT07717177
Age 70 years to Not stated (registered criteria)
Led by Ruijin HospitalShanghai
- Not yet recruitingA Multicenter, Prospective, Open-Label, Randomized Controlled Clinical Study of Orelabrutinib Combined With Obinutuzumab and Lenalidomide Versus Obinutuzumab Plus Chemotherapy for Treatment-Naive Follicular Lymphoma
- Phase
- Phase 3
- Started
- 2026-07
- Posted
- Registry
- NCT07719855
Age 18 years to Not stated (registered criteria)
Led by Ruijin HospitalShanghai
- Not yet recruitingGELAD-Based Response-Adapted Treatment for Early-Stage Extranodal NK/T-Cell Lymphoma
- Phase
- Phase 2
- Started
- 2026-09
- Posted
- Registry
- NCT07768943
Age 18 years to 75 years (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- Not yet recruitingA Phase 3 Study to Compare the Efficacy of ICP-248 in Combination With Orelabrutinib Versus Pirtobrutinib in Participants With Relapsed or Refractory Mantle Cell Lymphoma (r/r MCL).
- Phase
- Phase 3
- Started
- 2026-10
- Posted
- Registry
- NCT07784101
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 24 listed hospitals as study sitesBeijing, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Hefei, Jinan, Kunming, Nanjing, Shanghai, Shenyang, Shijiazhuang, Tianjin, Wuhan, Xi'an, Zhengzhou
- Not yet recruitingPirtobrutinib Plus Methotrexate-Based Chemoimmunotherapy for Systemic DLBCL With CNS Involvement
- Phase
- Phase 2
- Started
- 2026-09
- Posted
- Registry
- NCT07812493
Age 14 years to 80 years (registered criteria)
Led by Ruijin HospitalShanghai
- Not yet recruitingA Phase II Study of TT-01488 Tablets in Combination With Anti-CD20 Monoclonal Antibody Therapy in Patients With Mantle Cell Lymphoma
- Phase
- Phase 2
- Started
- 2026-10
- Posted
- Registry
- NCT07855016
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 2 listed hospitals as study sitesGuangzhou, Shanghai
- Not yet recruitingOrelabrutinib Plus ICP 248 vs Orelabrutinib for Relapsed/Refractory Marginal Zone Lymphoma
- Phase
- Phase 3
- Started
- 2026-10
- Posted
- Registry
- NCT07896590
Age 18 years to Not stated (registered criteria)
Lead sponsor is not a listed hospital; 40 listed hospitals as study sitesBeijing, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Haikou, Hangzhou, Harbin, Hefei, Jinan, Kunming, Lanzhou, Luoyang, Nanchang, Nanjing, Shanghai, Shenyang, Shijiazhuang, Taiyuan, Tianjin, Wuhan, Xi'an, Xiamen, Zhengzhou
- Not yet recruitingOrelabrutinib Plus 4 Gy Radiotherapy Versus 24 Gy Radiotherapy for Stage I/II MALT Lymphoma
- Phase
- Phase 2
- Started
- 2026-11
- Posted
- Registry
- NCT07945353
Age 18 years to Not stated (registered criteria)
Led by Fudan University Shanghai Cancer CenterShanghai
- Not yet recruitingThe Value of Artificial Intelligence-based 18F-FDG PET/CT in Diferential Diagnosis, Efficacy Prediction and Prognosis Prediction of T-NK Cell Lymphoma: a Clinical Study
- Phase
- Not given
- Started
- 2025-01
- Posted
- Registry
- NCT06747299
Age 18 years to 75 years (registered criteria)
Led by Ruijin HospitalShanghai
- Not yet recruitingMechanistic Study of EBV mRNA Vaccine (WGc-043) in EBV-Positive Relapsed/Refractory Lymphoma
- Phase
- Not given
- Started
- 2025-04
- Posted
- Registry
- NCT06788600
Age 18 years to 75 years (registered criteria)
Led by Ruijin HospitalShanghai
- Not yet recruitingThe Value of PET Imaging Targeting Granzyme B in Predicting Efficacy and Prognosis in T-NK Cell Lymphoma
- Phase
- Not given
- Started
- 2025-03
- Posted
- Registry
- NCT06863441
Age 18 years to Not stated (registered criteria)
Led by Ruijin HospitalShanghai
- Not yet recruitingStudy to Evaluate the Efficacy and Safety of Axicabtagene Ciloleucel Injection as First-Line Therapy of High-Risk Large B-Cell Lymphoma
- Phase
- N/A
- Started
- 2025-04
- Posted
- Registry
- NCT06935136
Age 18 years to Not stated (registered criteria)
Led by Ruijin HospitalShanghai
- Not yet recruitingPirtobrutinib in Combination With Rituximab, Gemcitabine, Oxaliplatin With or Without Polatuzumab Vedotin in Covalent BTK Inhibitor-Pretreated Relapsed/Refractory Diffuse Large B-Cell Lymphoma
- Phase
- Phase 2
- Started
- 2025-08
- Posted
- Registry
- NCT07122609
Age 18 years to Not stated (registered criteria)
Led by Ruijin HospitalShanghai
- Not yet recruitingEvaluation of the Efficacy and Safety of TQB2825 Injection Compared to Immunotherapy in the Treatment of Recurrent/Refractory Follicular Lymphoma
- Phase
- Phase 3
- Started
- 2025-11
- Posted
- Registry
- NCT07187960
Age 18 years to 80 years (registered criteria)
Lead sponsor is not a listed hospital; 19 listed hospitals as study sitesBeijing, Chongqing, Guiyang, Haikou, Lanzhou, Linyi, Nanchang, Nanjing, Shanghai, Shenyang, Taiyuan, Tianjin, Wuhan, Xi'an, Yantai, Zhengzhou
- Not yet recruitingThe Efficacy and Safety of Chidamide, Anti-PD-1 Antibody in Combination With Pegaspargase Versus DDGP in the Treatment of Newly Diagnosed, Stage III to IV Extranodal Natural Killer/T-Cell Lymphoma
- Phase
- Phase 3
- Started
- 2024-02
- Posted
- Registry
- NCT06255795
Age 14 years to 70 years (registered criteria)
Led by Ruijin HospitalShanghai
- Not yet recruitingZanubrutinib, Obinutuzumab and Lenalidomide (ZGR) in High-risk Treatment-naive Patients with Follicular Lymphoma (FL)
- Phase
- Phase 2
- Started
- 2024-12
- Posted
- Registry
- NCT06549335
Age 18 years to Not stated (registered criteria)
Led by Ruijin HospitalShanghai
- Not yet recruitingJWCAR201 for the Treatment of Hematology Malignancy and Autoimmune Diseases
- Phase
- Phase 1
- Started
- 2024-09
- Posted
- Registry
- NCT06567080
Age 18 years to 70 years (registered criteria)
Led by Renji HospitalShanghai
- Not yet recruitingCAR T-cell Therapy in Combination With Glofitamab for Relapsed/Refractory Large B-Cell Lymphoma With High-Risk Prognostic Factors
- Phase
- Phase 2
- Started
- 2024-09
- Posted
- Registry
- NCT06567366
Age 18 years to Not stated (registered criteria)
Led by Ruijin HospitalShanghai
- Not yet recruitingARTA-based Chemo-free Bridging/Maintenance Therapy in CAR-T Treatment for High-Risk R/R B-NHL Ineligible for HDCT and ASCT
- Phase
- Phase 2
- Started
- 2024-12
- Posted
- Registry
- NCT06646666
Age 18 years to Not stated (registered criteria)
Led by Ruijin HospitalShanghai
- Not yet recruitingThe Effectiveness and Safety of Glofitamab in Real-World Clinical Practice Among Chinese Adult Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma: A Prospective, Observational, Multicenter Study
- Phase
- Not given
- Started
- 2024-10
- Posted
- Registry
- NCT06656234
Age 18 years to Not stated (registered criteria)
Led by Ruijin HospitalShanghai
- Not yet recruitingReal World Study of Linperlisib for Lymphoma Treatment
- Phase
- Not given
- Started
- 2023-05
- Posted
- Registry
- NCT05863871
Age 18 years to Not stated (registered criteria)
Led by Ruijin Hospital; 1 listed hospital as study siteShanghai, Tianjin
- Not yet recruitingSelinexor Combined With R-GDP Regimen for TP53-altered R/R DLBCL
- Phase
- Phase 2
- Started
- 2023-10
- Posted
- Registry
- NCT06062641
Age 18 years to Not stated (registered criteria)
Led by Ruijin HospitalShanghai
- Enrolling by invitationReal-world Study of Acalabrutinib
- Phase
- Not given
- Started
- 2024-07
- Posted
- Registry
- NCT06767891
Age 18 years to Not stated (registered criteria)
Led by Ruijin HospitalShanghai
- Enrolling by invitationEfficacy and Safety of Tislelizumab Combined With Gemcitabine and Peraspartase in the Treatment of Patients With Primary Stage I-II NK/T Cell Lymphoma
- Phase
- Not given
- Started
- 2024-09
- Posted
- Registry
- NCT07450040
Age 18 years to 70 years (registered criteria)
Led by Eye & ENT Hospital of Fudan UniversityShanghai
Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.
Disease research in Shanghai
Each number is papers led on that disease, 2021–2025. “Open” counts open trials the hospital leads. Hospitals A–Z; this is not a ranking.
A blank cell means no papers or trials were found in these records. It does not mean the hospital does not treat that disease.
| Cancer | Blood disorders | Other diseases | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hospital | Nasopharyngeal carcinoma | Oesophageal squamous cell carcinoma | Hepatocellular carcinoma | Stomach cancer | Lung cancer | Pancreatic cancer | Breast cancer | Glioma | Hepatoblastoma | Retinoblastoma | Chordoma | Osteosarcoma | Gastrointestinal stromal tumour | Neuroblastoma | Ewing sarcoma | Multiple myeloma | B-cell acute lymphoblastic leukaemia | Aplastic anaemia | Haemophagocytic lymphohistiocytosis | Lymphoma | Beta thalassaemia | Haemophilia A | Atypical haemolytic uraemic syndrome | Thrombotic thrombocytopenic purpura | Fanconi anaemia | Neuromyelitis optica spectrum disorder | IgG4-related disease | Myasthenia gravis | Moyamoya disease | Wilson disease | Biliary atresia | Coronary heart disease | Congenital heart disease | Scoliosis | Anti-NMDA receptor encephalitis | Takayasu arteritis | Hepatic echinococcosis | Idiopathic pulmonary fibrosis | Lymphangioleiomyomatosis | Amyotrophic lateral sclerosis | Spinal muscular atrophy | Fabry disease | Pompe disease | Duchenne muscular dystrophy | Behçet disease | Alport syndrome | IgA nephropathy | Gaucher disease | Niemann–Pick disease type C | Osteogenesis imperfecta | Primary biliary cholangitis | Primary sclerosing cholangitis | Congenital diaphragmatic hernia | Hirschsprung disease | Inherited epidermolysis bullosa | Hereditary angioedema | Familial adenomatous polyposis | Leber hereditary optic neuropathy | Majeed syndrome | NGLY1 deficiency | ISG15 deficiency | Shortlist |
| Cancer Hospital, Fudan University | none | none | none | none | none | none | 01 open | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Changhai Hospital海军军医大学第一附属医院(长海医院) | 2 | 221 open | 19 | 315 open | 201 open | 8812 open | 101 open | 7 | none | 2 | none | 1 | 1 | 0 | none | none | none | none | none | 9 | none | none | none | none | none | none | 01 open | none | none | none | none | 4 | 1 | 7 | none | 1 | none | 2 | none | none | none | none | none | none | 1 | none | 1 | none | none | none | 1 | none | 0 | 0 | 1 | none | 0 | none | none | none | none | |
| Changzheng Hospital海军军医大学第二附属医院(长征医院) | none | 3 | 151 open | 171 open | 40 | 41 open | none | 10 | none | none | 5 | 16 | 4 | 0 | 2 | 262 open | none | none | none | 6 | none | none | none | 1 | none | none | none | none | none | none | none | 5 | none | 8 | 1 | none | none | 2 | none | 0 | none | none | none | none | 1 | none | 5 | none | none | 2 | 1 | none | none | none | none | none | 1 | none | none | none | none | |
| Child Health Hospital | none | none | none | none | none | none | 26 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 8 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Children Hospital, Fudan University | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Children's Hospital of Fudan University复旦大学附属儿科医院 | none | none | none | none | none | none | none | 11 | 5 | 0 | 0 | 4 | none | 11 | 1 | none | 0 | none | 0 | 5 | 01 open | none | 1 | none | none | none | none | 1 | 2 | none | 213 open | 5 | 372 open | 3 | 1 | 0 | none | none | none | none | 3 | 11 open | 0 | 2 | 1 | 0 | 2 | 1 | none | 1 | none | 1 | 0 | 4 | 2 | none | 0 | none | 1 | 0 | none | |
| Dahua Hospital | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| East Hospital上海市东方医院 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 0 | none | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Eastern Hepatobiliary Surgery Hospital海军军医大学第三附属医院(东方肝胆外科医院) | none | none | 2144 open | 6 | none | 7 | none | none | none | none | none | 4 | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 0 | 0 | none | none | none | none | none | none | none | none | none | |
| Eye & ENT Hospital of Fudan University复旦大学附属眼耳鼻喉科医院 | 324 open | none | none | none | none | none | none | none | none | 63 open | 0 | none | none | 51 open | none | none | none | none | none | 161 open | none | none | none | none | none | none | none | none | none | none | none | none | 17 | none | none | 0 | none | none | none | none | none | none | none | none | 0 | none | none | none | none | none | none | none | none | none | none | none | none | 1 | none | none | none | |
| Fengxian District Central Hospital上海市奉贤区中心医院 | none | 3 | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Fifth People's Hospital of Fudan University复旦大学附属上海市第五人民医院 | none | none | none | none | none | 2 | none | none | none | none | 1 | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 4 | none | none | none | none | 4 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| First Affiliated Hospital of Naval Medical University | none | none | none | none | none | 6 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| First Rehabilitation Hospital, Tongji University上海市第一康复医院 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 2 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Fudan University Shanghai Cancer Center复旦大学附属肿瘤医院 | 381 open | 328 open | 542 open | 8817 open | 24331 open | 21211 open | 39090 open | 15 | none | none | 3 | 6 | 0 | none | 4 | none | 0 | none | none | 3318 open | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | |
| Gongli Hospital上海市浦东新区公利医院 | none | none | none | none | none | none | none | none | none | none | none | 0 | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Guangming Traditional Chinese Medicine Hospital上海市浦东新区光明中医医院 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Gynecology Hospital, Fudan University复旦大学附属妇产科医院 | none | none | none | none | none | none | 17 | none | none | none | none | 0 | none | 2 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Health Sciences Affiliated Zhoupu Hospital上海市浦东新区周浦医院 | none | none | none | none | none | none | none | none | none | none | none | 1 | 1 | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 2 | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Huadong Hospital, Fudan University复旦大学附属华东医院 | none | 11 open | none | 41 open | 42 | 111 open | none | none | none | none | none | 0 | none | none | none | none | none | none | 0 | 6 | none | none | none | none | none | none | none | none | 2 | none | none | 14 | none | none | none | none | none | 0 | none | 0 | none | none | none | none | 24 | none | 1 | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | |
| Huashan Hospital复旦大学附属华山医院 | none | 12 | 621 open | 226 open | 62 | 191 open | 261 open | 1226 open | none | none | 4 | 2 | 0 | 1 | 0 | 5 | none | none | none | 351 open | none | 1 | none | none | none | 231 open | 0 | 314 open | 17 | none | none | 5 | 3 | none | 1 | none | none | 7 | none | 10 | 11 | none | 1 | 1 | 1 | none | 6 | none | none | none | 0 | 0 | none | none | 2 | 1 | none | none | none | none | none | |
| Infant Hospital上海市第一妇婴保健院 | none | none | none | none | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 3 | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Jiading District Anting Hospital上海市嘉定区安亭医院 | none | none | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Jiahui International Hospital上海嘉会国际医院 | none | none | none | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Jing'an District Centre Hospital上海市静安区中心医院 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | 2 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Jinshan Hospital, Fudan University复旦大学附属金山医院 | none | none | none | none | none | none | none | none | none | none | none | 5 | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | |
| Longhua Hospital上海中医药大学附属龙华医院 | none | 7 | 11 | 13 | 44 | none | 36 | none | none | none | 1 | 4 | none | 1 | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | 51 open | none | 2 | none | none | none | 1 | none | none | none | none | none | none | none | none | 1 | none | none | none | 2 | 0 | none | none | none | none | 1 | none | none | none | none | |
| Minhang Hospital上海市闵行区中心医院 | none | none | none | 9 | none | none | none | none | none | none | none | 2 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Putuo Hospital上海市普陀区中心医院 | none | none | none | none | none | none | none | none | none | none | none | 0 | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Renji Hospital上海交通大学医学院附属仁济医院 | 22 open | 81 open | 1045 open | 655 open | 883 open | 1037 open | 7620 open | 251 open | 3 | 1 | 1 | 3 | 10 | 2 | none | 242 open | none | none | 3 | 232 open | none | none | 1 | none | none | 111 open | 2 | 31 open | none | none | 3 | 11 | 10 | 0 | 2 | 0 | none | 0 | none | 3 | none | 1 | none | 0 | 2 | none | 6 | none | none | none | 171 open | 5 | none | none | none | 2 | none | none | none | none | none | |
| Ruijin Hospital上海交通大学医学院附属瑞金医院 | none | 221 open | 353 open | 9613 open | 6811 open | 11418 open | 11518 open | 14 | none | none | none | 131 open | 2 | 2 | 0 | 22 | 114 open | none | 2 | 9755 open | 0 | 5 | none | 0 | none | none | none | none | 2 | none | none | 594 open | 2 | 1 | 1 | none | none | 0 | 2 | 2 | 0 | 3 | none | none | none | 1 | 42 open | none | none | none | 0 | none | none | none | none | none | 2 | none | none | none | none | |
| Seventh People's Hospital of Shanghai University of Traditional Chinese Medicine上海市第七人民医院 | none | none | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Shanghai Baoshan Luodian Hospital上海市宝山区罗店医院 | none | none | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Shanghai Chest Hospital上海市胸科医院 | none | 4012 open | none | none | 41445 open | none | none | none | none | none | none | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 11 | 4 | none | none | none | none | 3 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Shanghai Children's Hospital上海市儿童医院 | none | none | none | none | none | none | none | none | none | none | none | 1 | none | 6 | 1 | none | 1 | none | 1 | none | 4 | 0 | none | none | none | none | none | none | none | none | 1 | none | 10 | 2 | none | none | none | none | none | none | none | none | none | 2 | 0 | 0 | 0 | 0 | none | none | none | none | 2 | none | none | none | none | none | none | none | none | |
| Shanghai Children's Medical Center上海交通大学医学院附属上海儿童医学中心 | none | none | none | none | none | none | none | none | 171 open | none | none | 0 | none | 11 | 0 | none | 81 open | 5 | none | 11 | 0 | none | none | none | 2 | none | none | none | none | none | none | none | 971 open | 2 | none | none | none | none | none | none | 0 | 0 | 0 | 02 open | none | none | 3 | 0 | none | none | none | none | 2 | 2 | 1 | none | none | none | none | none | none | |
| Shanghai East Hospital, Tongji University同济大学附属东方医院 | 1 | 13 | 36 | 37 | 502 open | 12 | 50 | 13 | none | 0 | 1 | 2 | 2 | 2 | 1 | 13 | none | none | none | 7 | none | none | none | none | 1 | none | none | none | none | none | none | 201 open | 11 | none | none | none | none | 4 | none | 11 open | none | none | none | none | none | none | 1 | none | none | none | 0 | none | none | none | none | none | none | none | none | none | none | |
| Shanghai Eighth People Hospital上海市第八人民医院 | none | none | none | none | none | none | none | none | none | 1 | none | 2 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Shanghai Electric Power Hospital上海电力医院 | none | none | none | none | none | none | none | none | none | none | none | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Shanghai Fengxian District Central Hospital | none | none | none | none | 0 | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Shanghai Fourth People's Hospital同济大学附属上海市第四人民医院 | none | none | none | none | none | none | none | none | 1 | none | none | 1 | none | none | none | 31 open | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Shanghai General Hospital上海市第一人民医院 | 5 | 3 | 361 open | 271 open | 494 open | 357 open | 62 | 13 | none | 1 | 5 | 24 | 2 | 0 | none | 2 | 0 | 0 | none | 118 open | none | 0 | none | none | none | none | none | none | none | none | none | 25 | 4 | none | 1 | 1 | none | 1 | none | 1 | none | none | none | none | none | none | 0 | none | none | none | none | 0 | none | none | none | none | none | 2 | none | none | none | |
| Shanghai Jiading Central Hospital上海市嘉定区中心医院 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 0 | none | none | none | none | none | none | none | none | none | none | |
| Shanghai Mengchao Cancer Hospital | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Shanghai Mental Health Center上海市精神卫生中心 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Shanghai Municipal Hospital, Shanghai University of Traditional Chinese Medicine上海市中医医院 | none | none | none | none | 28 | none | none | none | none | none | none | 2 | none | 1 | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 0 | none | none | none | 1 | 1 | none | none | none | none | none | none | none | none | none | |
| Shanghai Ninth People's Hospital上海交通大学医学院附属第九人民医院 | 5 | 4 | none | none | 33 | 11 | 27 | 9 | none | 29 | none | 15 | 1 | 2 | none | none | none | none | none | 221 open | none | 1 | none | none | 1 | none | none | none | none | none | none | 15 | 0 | 2 | none | 0 | none | 4 | none | none | 0 | none | none | 1 | 1 | none | 0 | none | none | 1 | 0 | none | none | 0 | 1 | none | none | 1 | none | none | none | |
| Shanghai Proton and Heavy Ion Center上海市质子重离子医院 | 0 | none | 2 | none | 63 open | 01 open | 13 open | 2 | none | none | 0 | none | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Shanghai Pudong Hospital上海市浦东医院 | none | none | none | none | none | 2 | 10 | 6 | none | 0 | none | 0 | none | none | none | 1 | 0 | none | none | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Shanghai Pudong New Area People's Hospital上海市浦东新区人民医院 | none | none | none | none | none | none | none | none | none | none | none | 0 | none | 0 | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Shanghai Pulmonary Hospital上海市肺科医院 | none | 5 | none | none | 39443 open | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 0 | none | none | none | none | none | none | none | none | none | 71 open | none | none | none | none | none | none | 0 | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Shanghai Putuo District Liqun Hospital上海市普陀区利群医院 | none | none | none | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Shanghai Sixth People's Hospital上海市第六人民医院 | 3 | 0 | 27 | 21 | 43 | 15 | 43 | 8 | none | none | 0 | 35 | 0 | 4 | 1 | 1 | none | none | none | none | none | none | none | none | none | 2 | none | none | none | none | none | 11 | 2 | none | none | none | none | 2 | none | 4 | none | none | none | 0 | none | 0 | 0 | none | none | 7 | 1 | 1 | none | none | none | none | 0 | none | none | none | none | |
| Shanghai Songjiang District Central Hospital上海市松江区中心医院 | none | none | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Shanghai Stomatological Hospital上海市口腔医院 | none | none | none | none | none | none | none | none | none | none | none | 2 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Shanghai Tenth People's Hospital上海市第十人民医院 | none | 3 | 27 | 21 | 61 | 14 | 44 | 12 | 3 | none | 0 | 21 | 0 | 2 | 0 | 5 | none | none | none | 10 | none | none | none | none | none | none | none | none | none | none | none | 27 | none | none | none | 2 | none | 2 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Shanghai Tong Ren Hospital上海市同仁医院 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 0 | none | none | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Shanghai Xuhui Central Hospital上海徐汇中心医院 | none | none | none | none | none | none | none | none | 1 | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 0 | none | none | none | none | none | none | none | none | 0 | none | none | none | 0 | none | none | none | none | none | none | none | none | none | none | |
| Shibei Hospital上海市静安区市北医院 | none | none | none | none | none | none | none | none | none | none | none | 0 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Shuguang Hospital上海中医药大学附属曙光医院 | none | none | 20 | none | none | none | none | none | none | none | none | 1 | none | 0 | 0 | none | none | none | none | none | none | 1 | none | none | 1 | none | none | none | none | none | none | none | none | 2 | none | none | none | 3 | none | none | none | none | none | none | none | none | 3 | none | none | none | 1 | 1 | none | none | none | none | none | none | none | none | none | |
| Tongji Hospital同济大学附属同济医院 | none | 3 | none | 17 | 30 | none | none | 9 | none | none | none | 2 | 1 | 2 | none | 21 open | 01 open | 0 | none | 185 open | none | none | none | none | none | none | none | none | none | none | none | 9 | 2 | none | none | none | none | 2 | none | 0 | none | none | none | none | 0 | none | 0 | none | none | none | none | 0 | none | none | none | none | none | none | none | none | none | |
| Xinhua Hospital上海交通大学医学院附属新华医院 | none | none | 21 | 24 | 32 | 12 | 28 | 32 | 1 | 5 | none | 4 | 0 | 17 | 0 | 2 | none | none | none | 7 | none | none | none | none | none | none | none | 2 | none | 2 | 9 | 7 | 363 open | 33 | 0 | none | none | 0 | none | 1 | 0 | 1 | 0 | 0 | 0 | 01 open | 2 | 21 open | 1 | 0 | 1 | 0 | 3 | 6 | 4 | none | none | none | none | none | none | |
| Xinshijie Zhongxing Eye Hospital上海新视界中兴眼科医院 | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Yangpu Hospital上海市杨浦区中心医院 | none | none | none | none | none | none | none | none | none | none | none | 0 | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Yangzhi Rehabilitation Hospital, Tongji University上海市养志康复医院 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 2 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Yueyang Hospital, Shanghai University of Traditional Chinese Medicine上海中医药大学附属岳阳中西医结合医院 | none | none | none | none | none | none | none | none | none | none | none | 1 | none | none | none | 3 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 2 | none | none | none | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | 1 | none | none | none | none | 1 | none | none | none | none | |
| Zhabei Central Hospital上海市静安区闸北中心医院 | none | none | none | none | none | none | none | none | none | none | none | 0 | none | none | none | 7 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
| Zhongshan Hospital, Fudan University复旦大学附属中山医院 | 3 | 568 open | 40816 open | 1348 open | 1864 open | 779 open | 441 open | 19 | 3 | none | 0 | 5 | 28 | 0 | 2 | 234 open | none | none | none | 142 open | 1 | none | none | none | none | 0 | 4 | 11 open | none | none | none | 10914 open | 30 | none | 0 | 332 open | none | 3 | 1 | 3 | none | none | none | 1 | 2 | none | 4 | none | none | 1 | 0 | none | none | none | 1 | none | 0 | none | none | none | none | |
| Zhongshan-Xuhui Hospital上海市徐汇区中心医院 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | 1 | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | none | |
Column labels are short names. Choose one to open that disease in Shanghai.
- Nasopharyngeal carcinoma 2
- Oesophageal squamous cell carcinoma 221 open
- Hepatocellular carcinoma 19
- Stomach cancer 315 open
- Lung cancer 201 open
- Pancreatic cancer 8812 open
- Breast cancer 101 open
- Glioma 7
- Retinoblastoma 2
- Osteosarcoma 1
- Gastrointestinal stromal tumour 1
- Neuroblastoma 0
- Lymphoma 9
- IgG4-related disease 01 open
- Coronary heart disease 4
- Congenital heart disease 1
- Scoliosis 7
- Takayasu arteritis 1
- Idiopathic pulmonary fibrosis 2
- Behçet disease 1
- IgA nephropathy 1
- Primary biliary cholangitis 1
- Congenital diaphragmatic hernia 0
- Hirschsprung disease 0
- Inherited epidermolysis bullosa 1
- Familial adenomatous polyposis 0
- Oesophageal squamous cell carcinoma 3
- Hepatocellular carcinoma 151 open
- Stomach cancer 171 open
- Lung cancer 40
- Pancreatic cancer 41 open
- Glioma 10
- Chordoma 5
- Osteosarcoma 16
- Gastrointestinal stromal tumour 4
- Neuroblastoma 0
- Ewing sarcoma 2
- Multiple myeloma 262 open
- Lymphoma 6
- Thrombotic thrombocytopenic purpura 1
- Coronary heart disease 5
- Scoliosis 8
- Anti-NMDA receptor encephalitis 1
- Idiopathic pulmonary fibrosis 2
- Amyotrophic lateral sclerosis 0
- Behçet disease 1
- IgA nephropathy 5
- Osteogenesis imperfecta 2
- Primary biliary cholangitis 1
- Familial adenomatous polyposis 1
- Glioma 11
- Hepatoblastoma 5
- Retinoblastoma 0
- Chordoma 0
- Osteosarcoma 4
- Neuroblastoma 11
- Ewing sarcoma 1
- B-cell acute lymphoblastic leukaemia 0
- Haemophagocytic lymphohistiocytosis 0
- Lymphoma 5
- Beta thalassaemia 01 open
- Atypical haemolytic uraemic syndrome 1
- Myasthenia gravis 1
- Moyamoya disease 2
- Biliary atresia 213 open
- Coronary heart disease 5
- Congenital heart disease 372 open
- Scoliosis 3
- Anti-NMDA receptor encephalitis 1
- Takayasu arteritis 0
- Spinal muscular atrophy 3
- Fabry disease 11 open
- Pompe disease 0
- Duchenne muscular dystrophy 2
- Behçet disease 1
- Alport syndrome 0
- IgA nephropathy 2
- Gaucher disease 1
- Osteogenesis imperfecta 1
- Primary sclerosing cholangitis 1
- Congenital diaphragmatic hernia 0
- Hirschsprung disease 4
- Inherited epidermolysis bullosa 2
- Familial adenomatous polyposis 0
- Majeed syndrome 1
- NGLY1 deficiency 0
- Nasopharyngeal carcinoma 381 open
- Oesophageal squamous cell carcinoma 328 open
- Hepatocellular carcinoma 542 open
- Stomach cancer 8817 open
- Lung cancer 24331 open
- Pancreatic cancer 21211 open
- Breast cancer 39090 open
- Glioma 15
- Chordoma 3
- Osteosarcoma 6
- Gastrointestinal stromal tumour 0
- Ewing sarcoma 4
- B-cell acute lymphoblastic leukaemia 0
- Lymphoma 3318 open
- Familial adenomatous polyposis 1
- Oesophageal squamous cell carcinoma 11 open
- Stomach cancer 41 open
- Lung cancer 42
- Pancreatic cancer 111 open
- Osteosarcoma 0
- Haemophagocytic lymphohistiocytosis 0
- Lymphoma 6
- Moyamoya disease 2
- Coronary heart disease 14
- Idiopathic pulmonary fibrosis 0
- Amyotrophic lateral sclerosis 0
- Behçet disease 24
- IgA nephropathy 1
- Congenital diaphragmatic hernia 1
- Oesophageal squamous cell carcinoma 12
- Hepatocellular carcinoma 621 open
- Stomach cancer 226 open
- Lung cancer 62
- Pancreatic cancer 191 open
- Breast cancer 261 open
- Glioma 1226 open
- Chordoma 4
- Osteosarcoma 2
- Gastrointestinal stromal tumour 0
- Neuroblastoma 1
- Ewing sarcoma 0
- Multiple myeloma 5
- Lymphoma 351 open
- Haemophilia A 1
- Neuromyelitis optica spectrum disorder 231 open
- IgG4-related disease 0
- Myasthenia gravis 314 open
- Moyamoya disease 17
- Coronary heart disease 5
- Congenital heart disease 3
- Anti-NMDA receptor encephalitis 1
- Idiopathic pulmonary fibrosis 7
- Amyotrophic lateral sclerosis 10
- Spinal muscular atrophy 11
- Pompe disease 1
- Duchenne muscular dystrophy 1
- Behçet disease 1
- IgA nephropathy 6
- Primary biliary cholangitis 0
- Primary sclerosing cholangitis 0
- Inherited epidermolysis bullosa 2
- Hereditary angioedema 1
- Oesophageal squamous cell carcinoma 7
- Hepatocellular carcinoma 11
- Stomach cancer 13
- Lung cancer 44
- Breast cancer 36
- Chordoma 1
- Osteosarcoma 4
- Neuroblastoma 1
- Haemophilia A 1
- Coronary heart disease 51 open
- Scoliosis 2
- Idiopathic pulmonary fibrosis 1
- IgA nephropathy 1
- Primary biliary cholangitis 2
- Primary sclerosing cholangitis 0
- Familial adenomatous polyposis 1
- Nasopharyngeal carcinoma 22 open
- Oesophageal squamous cell carcinoma 81 open
- Hepatocellular carcinoma 1045 open
- Stomach cancer 655 open
- Lung cancer 883 open
- Pancreatic cancer 1037 open
- Breast cancer 7620 open
- Glioma 251 open
- Hepatoblastoma 3
- Retinoblastoma 1
- Chordoma 1
- Osteosarcoma 3
- Gastrointestinal stromal tumour 10
- Neuroblastoma 2
- Multiple myeloma 242 open
- Haemophagocytic lymphohistiocytosis 3
- Lymphoma 232 open
- Atypical haemolytic uraemic syndrome 1
- Neuromyelitis optica spectrum disorder 111 open
- IgG4-related disease 2
- Myasthenia gravis 31 open
- Biliary atresia 3
- Coronary heart disease 11
- Congenital heart disease 10
- Scoliosis 0
- Anti-NMDA receptor encephalitis 2
- Takayasu arteritis 0
- Idiopathic pulmonary fibrosis 0
- Amyotrophic lateral sclerosis 3
- Fabry disease 1
- Duchenne muscular dystrophy 0
- Behçet disease 2
- IgA nephropathy 6
- Primary biliary cholangitis 171 open
- Primary sclerosing cholangitis 5
- Hereditary angioedema 2
- Oesophageal squamous cell carcinoma 221 open
- Hepatocellular carcinoma 353 open
- Stomach cancer 9613 open
- Lung cancer 6811 open
- Pancreatic cancer 11418 open
- Breast cancer 11518 open
- Glioma 14
- Osteosarcoma 131 open
- Gastrointestinal stromal tumour 2
- Neuroblastoma 2
- Ewing sarcoma 0
- Multiple myeloma 22
- B-cell acute lymphoblastic leukaemia 114 open
- Haemophagocytic lymphohistiocytosis 2
- Lymphoma 9755 open
- Beta thalassaemia 0
- Haemophilia A 5
- Thrombotic thrombocytopenic purpura 0
- Moyamoya disease 2
- Coronary heart disease 594 open
- Congenital heart disease 2
- Scoliosis 1
- Anti-NMDA receptor encephalitis 1
- Idiopathic pulmonary fibrosis 0
- Lymphangioleiomyomatosis 2
- Amyotrophic lateral sclerosis 2
- Spinal muscular atrophy 0
- Fabry disease 3
- Alport syndrome 1
- IgA nephropathy 42 open
- Primary biliary cholangitis 0
- Familial adenomatous polyposis 2
- Osteosarcoma 1
- Neuroblastoma 6
- Ewing sarcoma 1
- B-cell acute lymphoblastic leukaemia 1
- Haemophagocytic lymphohistiocytosis 1
- Beta thalassaemia 4
- Haemophilia A 0
- Biliary atresia 1
- Congenital heart disease 10
- Scoliosis 2
- Duchenne muscular dystrophy 2
- Behçet disease 0
- Alport syndrome 0
- IgA nephropathy 0
- Gaucher disease 0
- Congenital diaphragmatic hernia 2
- Hepatoblastoma 171 open
- Osteosarcoma 0
- Neuroblastoma 11
- Ewing sarcoma 0
- B-cell acute lymphoblastic leukaemia 81 open
- Aplastic anaemia 5
- Lymphoma 11
- Beta thalassaemia 0
- Fanconi anaemia 2
- Congenital heart disease 971 open
- Scoliosis 2
- Spinal muscular atrophy 0
- Fabry disease 0
- Pompe disease 0
- Duchenne muscular dystrophy 02 open
- IgA nephropathy 3
- Gaucher disease 0
- Congenital diaphragmatic hernia 2
- Hirschsprung disease 2
- Inherited epidermolysis bullosa 1
- Nasopharyngeal carcinoma 1
- Oesophageal squamous cell carcinoma 13
- Hepatocellular carcinoma 36
- Stomach cancer 37
- Lung cancer 502 open
- Pancreatic cancer 12
- Breast cancer 50
- Glioma 13
- Retinoblastoma 0
- Chordoma 1
- Osteosarcoma 2
- Gastrointestinal stromal tumour 2
- Neuroblastoma 2
- Ewing sarcoma 1
- Multiple myeloma 13
- Lymphoma 7
- Fanconi anaemia 1
- Coronary heart disease 201 open
- Congenital heart disease 11
- Idiopathic pulmonary fibrosis 4
- Amyotrophic lateral sclerosis 11 open
- IgA nephropathy 1
- Primary biliary cholangitis 0
- Nasopharyngeal carcinoma 5
- Oesophageal squamous cell carcinoma 3
- Hepatocellular carcinoma 361 open
- Stomach cancer 271 open
- Lung cancer 494 open
- Pancreatic cancer 357 open
- Breast cancer 62
- Glioma 13
- Retinoblastoma 1
- Chordoma 5
- Osteosarcoma 24
- Gastrointestinal stromal tumour 2
- Neuroblastoma 0
- Multiple myeloma 2
- B-cell acute lymphoblastic leukaemia 0
- Aplastic anaemia 0
- Lymphoma 118 open
- Haemophilia A 0
- Coronary heart disease 25
- Congenital heart disease 4
- Anti-NMDA receptor encephalitis 1
- Takayasu arteritis 1
- Idiopathic pulmonary fibrosis 1
- Amyotrophic lateral sclerosis 1
- IgA nephropathy 0
- Primary sclerosing cholangitis 0
- Leber hereditary optic neuropathy 2
- Nasopharyngeal carcinoma 5
- Oesophageal squamous cell carcinoma 4
- Lung cancer 33
- Pancreatic cancer 11
- Breast cancer 27
- Glioma 9
- Retinoblastoma 29
- Osteosarcoma 15
- Gastrointestinal stromal tumour 1
- Neuroblastoma 2
- Lymphoma 221 open
- Haemophilia A 1
- Fanconi anaemia 1
- Coronary heart disease 15
- Congenital heart disease 0
- Scoliosis 2
- Takayasu arteritis 0
- Idiopathic pulmonary fibrosis 4
- Spinal muscular atrophy 0
- Duchenne muscular dystrophy 1
- Behçet disease 1
- IgA nephropathy 0
- Osteogenesis imperfecta 1
- Primary biliary cholangitis 0
- Hirschsprung disease 0
- Inherited epidermolysis bullosa 1
- Leber hereditary optic neuropathy 1
- Nasopharyngeal carcinoma 3
- Oesophageal squamous cell carcinoma 0
- Hepatocellular carcinoma 27
- Stomach cancer 21
- Lung cancer 43
- Pancreatic cancer 15
- Breast cancer 43
- Glioma 8
- Chordoma 0
- Osteosarcoma 35
- Gastrointestinal stromal tumour 0
- Neuroblastoma 4
- Ewing sarcoma 1
- Multiple myeloma 1
- Neuromyelitis optica spectrum disorder 2
- Coronary heart disease 11
- Congenital heart disease 2
- Idiopathic pulmonary fibrosis 2
- Amyotrophic lateral sclerosis 4
- Duchenne muscular dystrophy 0
- Alport syndrome 0
- IgA nephropathy 0
- Osteogenesis imperfecta 7
- Primary biliary cholangitis 1
- Primary sclerosing cholangitis 1
- Familial adenomatous polyposis 0
- Oesophageal squamous cell carcinoma 3
- Hepatocellular carcinoma 27
- Stomach cancer 21
- Lung cancer 61
- Pancreatic cancer 14
- Breast cancer 44
- Glioma 12
- Hepatoblastoma 3
- Chordoma 0
- Osteosarcoma 21
- Gastrointestinal stromal tumour 0
- Neuroblastoma 2
- Ewing sarcoma 0
- Multiple myeloma 5
- Lymphoma 10
- Coronary heart disease 27
- Takayasu arteritis 2
- Idiopathic pulmonary fibrosis 2
- Oesophageal squamous cell carcinoma 3
- Stomach cancer 17
- Lung cancer 30
- Glioma 9
- Osteosarcoma 2
- Gastrointestinal stromal tumour 1
- Neuroblastoma 2
- Multiple myeloma 21 open
- B-cell acute lymphoblastic leukaemia 01 open
- Aplastic anaemia 0
- Lymphoma 185 open
- Coronary heart disease 9
- Congenital heart disease 2
- Idiopathic pulmonary fibrosis 2
- Amyotrophic lateral sclerosis 0
- Behçet disease 0
- IgA nephropathy 0
- Primary sclerosing cholangitis 0
- Hepatocellular carcinoma 21
- Stomach cancer 24
- Lung cancer 32
- Pancreatic cancer 12
- Breast cancer 28
- Glioma 32
- Hepatoblastoma 1
- Retinoblastoma 5
- Osteosarcoma 4
- Gastrointestinal stromal tumour 0
- Neuroblastoma 17
- Ewing sarcoma 0
- Multiple myeloma 2
- Lymphoma 7
- Myasthenia gravis 2
- Wilson disease 2
- Biliary atresia 9
- Coronary heart disease 7
- Congenital heart disease 363 open
- Scoliosis 33
- Anti-NMDA receptor encephalitis 0
- Idiopathic pulmonary fibrosis 0
- Amyotrophic lateral sclerosis 1
- Spinal muscular atrophy 0
- Fabry disease 1
- Pompe disease 0
- Duchenne muscular dystrophy 0
- Behçet disease 0
- Alport syndrome 01 open
- IgA nephropathy 2
- Gaucher disease 21 open
- Niemann–Pick disease type C 1
- Osteogenesis imperfecta 0
- Primary biliary cholangitis 1
- Primary sclerosing cholangitis 0
- Congenital diaphragmatic hernia 3
- Hirschsprung disease 6
- Inherited epidermolysis bullosa 4
- Nasopharyngeal carcinoma 3
- Oesophageal squamous cell carcinoma 568 open
- Hepatocellular carcinoma 40816 open
- Stomach cancer 1348 open
- Lung cancer 1864 open
- Pancreatic cancer 779 open
- Breast cancer 441 open
- Glioma 19
- Hepatoblastoma 3
- Chordoma 0
- Osteosarcoma 5
- Gastrointestinal stromal tumour 28
- Neuroblastoma 0
- Ewing sarcoma 2
- Multiple myeloma 234 open
- Lymphoma 142 open
- Beta thalassaemia 1
- Neuromyelitis optica spectrum disorder 0
- IgG4-related disease 4
- Myasthenia gravis 11 open
- Coronary heart disease 10914 open
- Congenital heart disease 30
- Anti-NMDA receptor encephalitis 0
- Takayasu arteritis 332 open
- Idiopathic pulmonary fibrosis 3
- Lymphangioleiomyomatosis 1
- Amyotrophic lateral sclerosis 3
- Duchenne muscular dystrophy 1
- Behçet disease 2
- IgA nephropathy 4
- Osteogenesis imperfecta 1
- Primary biliary cholangitis 0
- Inherited epidermolysis bullosa 1
- Familial adenomatous polyposis 0
Other cities nearby
Straight-line distance from the city centre; counts are hospitals listed for lymphoma.
Counts are listed hospitals only, not every hospital in each city.
Where these numbers come from
Papers
English-language PubMed papers, 2021–2025, where the first or last author lists the hospital first. Definitions
Trials
ClinicalTrials.gov records with the hospital as lead sponsor or site, as of 8 Nov 2026. Search Shanghai on ClinicalTrials.gov
Locations
Locations are shown at city centres. Check the hospital’s website for its address.